Nuclear Medicine and Molecular Imaging最新文献

{"title":"Current Prospects and Future Directions of Single Time Point Dosimetry in Radiopharmaceutical Therapy: A Systematic Review.","authors":"Mohammad Hossein Sadeghi, Sedigheh Sina, Teik Hin Tan, Saw Huey Ong, Kuangyu Shi, Kitiwat Khamwan, Chai Hong Yeong","doi":"10.1007/s13139-025-00917-1","DOIUrl":"10.1007/s13139-025-00917-1","url":null,"abstract":"<p><p>The rise of image-based approaches has reshaped personalized dosimetry in radiopharmaceutical therapies, holding the promise of reducing organ toxicity and tailoring treatments to individual responses. However, implementing these strategies accurately demands numerous quantitative scans and complex data processing, posing significant clinical hurdles. Therefore, simplified methodologies like single-time point (STP) dosimetry have emerged, aiming to enhance efficiency in clinical dosimetry. STP dosimetry estimates absorbed doses in radiopharmaceutical therapy from a singular measurement of time-integrated activity (TIA) at a specific time point. Following the PRISMA guidelines, a systematic exploration was performed on PubMed, ScienceDirect, Scopus, and Web of Science. This review encompasses research concentrating on organ dosimetry in patients employing STP dosimetry from January 2012 to December 2023. Evaluation of these chosen articles exposes a variety of uses for STP dosimetry, outlining its theoretical bases, practical applications, and discussions regarding its vital role in achieving a balance between eliminating tumors and reducing exposure to healthy tissues. From this review, STP dosimetry offers a hopeful path in simplifying personalized dosimetry by decreasing imaging intervals without sacrificing its accuracy. This innovative approach holds potential for routine dosimetry in clinical settings, potentially revolutionizing the landscape of radiopharmaceutical therapy.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 2","pages":"64-78"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13031474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Semi-Quantitative Parameters of ¹⁸F-FDG Digital PET/CT and Simultaneous PET/MRI in Lymphoma Patients.","authors":"Pimlapat Panperee, Supachoke Thongdonpua, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Dheeratama Siripongsatian, Jiratthakorn Keeratipiriyakul, Onanong Konggasame, Chanisa Chotipanich","doi":"10.1007/s13139-025-00962-w","DOIUrl":"10.1007/s13139-025-00962-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated the comparative performance of standardized uptake value (SUV) measurements derived from positron emission tomography/magnetic resonance imaging (PET/MRI) and digital positron emission tomography/computed tomography (PET/CT) in lymphoma patients. A retrospective analysis was conducted to compare semi-quantitative measures and assess the correlation and concordance between the two imaging modalities.</p><p><strong>Methods: </strong>A total of 106 lymphoma patients underwent both PET/CT and PET/MRI, either in the order of PET/CT followed by PET/MRI (PET/CT_first group, <i>n</i> = 51) or PET/MRI followed by PET/CT (PET/MRI_first group, <i>n</i> = 55). SUV measurements in lesions, liver, and mediastinal blood pool were compared between modalities.</p><p><strong>Results: </strong>SUV_max and SUV_mean were significantly lower in PET/MRI than PET/CT (<i>P</i> < 0.001), except SUV_mean for mediastinal blood pool in the PET/MRI_first group (<i>P</i> = 0.090). Correlation between modalities was very high for the lesions (ρ = 0.90-0.96). The Deauville five-point scale (D5PS) scores had good agreement between modalities (κ = 0.6566 for PET/CT_first and κ = 0.4846 for PET/MRI_first; <i>P</i> < 0.001), but the response categorization would have been different in 22/262 PET/CT_first group and 21/155 PET/MR_first group.</p><p><strong>Conclusion: </strong>SUV measurements from PET/MRI demonstrated strong correlation and good agreement in D5PS classification compared to digital PET/CT. Nonetheless, variations in PET subsystem technologies across modalities may influence quantitative values, and such differences should be carefully considered when interpreting results.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 2","pages":"131-139"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13031620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence Assisted ¹⁸F-FDG PET Radiomics in Classifying Histological Subtypes of Lung Cancer: Systematic Review and Meta-analysis.","authors":"Pooja Dwivedi, Sagar Barage, Ashish Jha, Archi Agrawal, Rajshri Singh, Sayak Choudhury, Venkatesh Rangarajan","doi":"10.1007/s13139-025-00922-4","DOIUrl":"10.1007/s13139-025-00922-4","url":null,"abstract":"<p><p>AI-assisted radiomics is an emerging tool for precision oncology, and many studies have recently shown promising results. However, there are still differences in whether it can be applied in clinical practice. This study aimed to evaluate the diagnostic accuracy of PET-based radiomics in ML models for histological subtype classification of lung cancer through a systematic review and meta-analysis. The study protocol was registered in PROSPERO, CRD42024603590. Methodological quality and risk of bias were assessed using QUADAS-2 and RQS. For the meta-analysis, validation data statistics were extracted from the studies with Type 2a or above as per the TRIPOD statement. A random-effects model was used to estimate the overall effect size. Statistical heterogeneity was assessed using the <i>I</i> ² value. Fourteen studies were included in the systematic review, of which eight were eligible for meta-analysis. All the studies were performed with internal validation. The average RQS across studies was 10.47 ± 4.72. Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were 0.81 (95% CI 0.65-0.90), 0.79 (95% CI 0.75-0.83), and 22.42 (95% CI 9.04-55.59), respectively. The SROC curve suggested good diagnostic performance with an AUC of 0.89 (95% CI 0.83-0.95). The meta-analysis revealed significant heterogeneity using Cochrane's <i>Q</i> test with <i>p</i> < 0.001. ML models utilizing ¹⁸F-FDG PET radiomics have the potential to predict histological subtypes of non-small cell lung cancer. External validation studies could provide stronger evidence for the generalizability.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13139-025-00922-4.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 2","pages":"79-92"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13031599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Status and Advancements in Radiotheranostics and Targeted Radionuclide Therapy in Malaysia.","authors":"Muhammad Fakhrurazi Ahmad Fadzil, Zarif Ashhar, Azahari Kasbollah, Zaitulhusna Md Safee, Siti Fazira Edzua Jamaludin, Akram Al-Ibraheem","doi":"10.1007/s13139-025-00963-9","DOIUrl":"https://doi.org/10.1007/s13139-025-00963-9","url":null,"abstract":"<p><p>Radiotheranostics is revolutionizing nuclear medicine by integrating diagnostic imaging and targeted radionuclide therapy using radiolabeled biomolecules. This paper highlights the current landscape of radiotheranostics in Malaysia, addressing advancements, challenges, and prospects for integrating novel biomolecules, enhancing infrastructure, and expanding access to personalized radiopharmaceutical therapies. Nuclear medicine centers in Malaysia have been operational for nearly sixty years, with approximately 40 facilities available country-wide and radiotheranostics is gaining momentum, particularly in the diagnosis and treatment of neuroendocrine tumors and prostate cancer using peptide receptor radionuclide therapy and prostate-specific membrane antigen-based theranostics. Despite significant progress, challenges such as limited local radionuclide production, uneven distribution of radiotheranostics centers, reliance on imports, and regulatory constraints hinder widespread adoption. The implementation of Malaysia's National Strategic Plan for Cancer Control Programme (2021-2025) underscores the growing need for sustainable theranostic solutions.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared Challenges, Shared Progress: A Colombian Perspective on the Regional Trajectory of Theragnostics.","authors":"Juan Martín Leguízamo-Isaza, Sara Ramírez-Aguirre, Patricia Bernal-Trujillo, Julián Rojas-Camacho","doi":"10.1007/s13139-025-00980-8","DOIUrl":"https://doi.org/10.1007/s13139-025-00980-8","url":null,"abstract":"","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"46-47"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear Cardiology Post-ISCHEMIA.","authors":"Sang-Geon Cho, Hee-Seung Henry Bom","doi":"10.1007/s13139-025-00972-8","DOIUrl":"https://doi.org/10.1007/s13139-025-00972-8","url":null,"abstract":"","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"57-59"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Explorative Analysis on the Role of Intraprostatic Visual Scores in PSMA PET-Guided Re-Irradiation for Recurrent Prostate Cancer.","authors":"Priscilla Guglielmo, Luciana di Cristina, Ciro Franzese, Rosario Mazzola, Jelena Jandric, Lucia Setti, Laura Evangelista","doi":"10.1007/s13139-025-00952-y","DOIUrl":"https://doi.org/10.1007/s13139-025-00952-y","url":null,"abstract":"<p><strong>Purpose: </strong>Up to one-third of patients treated with primary radiotherapy (RT) for prostate cancer (PCa) experience biochemical failure (BCF). In selected cases, re-irradiation represents a salvage option. PSMA PET/CT is a valuable tool for detecting intraprostatic recurrence and guiding re-treatment planning. Although visual scoring systems such as the PRIMARY score (PS) have been proposed, none are currently validated for this setting. This pilot study investigates the role of a visual classification system in optimizing salvage re-irradiation strategies.</p><p><strong>Methods: </strong>We retrospectively analysed patients with histologically confirmed PCa who underwent re-irradiation for intraprostatic recurrence, following PSMA PET/CT between 2021 and 2024. Only patients without extra-prostatic disease were included. Clinical, imaging, and treatment data were collected. Re-irradiation was delivered using image-guided volumetric modulated arc therapy. Outcomes included BCF and toxicity (CTCAE v5).</p><p><strong>Results: </strong>Thirteen patients (median age: 76 years) were included. The International Society of Urological Pathology (ISUP) grade group at diagnosis was 1-2 in ten patients and ≥ 4 in three. Median PSA at diagnosis and at re-irradiation was 9.43 and 2.22 ng/mL, respectively. PSMA PET/CT showed uptake in all cases (focal: 8, diffuse: 4, mixed: 1); PS was ≥ 4 in eight patients. Re-irradiation was delivered after a mean interval of 8.1 years, with a median dose of 30 Gy in 5 fractions. PET/CT guided target delineation in 11 cases. After 16 months of median follow-up, four patients had BCF, and two experienced mild toxicity (Grade 1).</p><p><strong>Conclusion: </strong>These preliminary findings highlight the limitations of visual interpretation alone; further optimization by Nuclear Medicine and Radiation Oncology specialists is needed to enhance BCF and limit local toxicities.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"12-20"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics Associated with High [⁶⁸Ga]Ga-PSMA-11 Uptake and Preliminary Therapeutic Outcomes in Patients with Metastatic Adenoid Cystic Carcinoma.","authors":"Hyunpil Sung, Minseok Suh, Joonhyung Gil, Bhumsuk Keam, Gi Jeong Cheon, Keon Wook Kang","doi":"10.1007/s13139-025-00955-9","DOIUrl":"10.1007/s13139-025-00955-9","url":null,"abstract":"<p><strong>Purpose: </strong>Adenoid cystic carcinoma (ACC) is a rare cancer that arises from the salivary glands. Recent studies have shown that prostate-specific membrane antigen (PSMA) expression is high in ACC. We conducted a prospective study to evaluate clinical factors associated with high [⁶⁸Ga]Ga-PSMA-11 uptake and to report preliminary therapeutic outcomes of ¹⁷⁷Lu-PSMA therapy in recurred or metastatic ACC.</p><p><strong>Materials and methods: </strong>Thirty patients were prospectively enrolled. Any focal accumulation of [⁶⁸Ga]Ga-PSMA-11 not explained by physiological uptake was defined as pathological lesions. Clinicopathological features relevant for high [⁶⁸Ga]Ga-PSMA-11 uptake in recurred or metastatic ACC were analyzed. Therapeutic outcomes of patients who received ¹⁷⁷Lu-PSMA therapy under compassionate use were also reviewed as a secondary component.</p><p><strong>Results: </strong>A total of 238 lesions were evaluated, and the SUV_max ranged between 0.9 and 11.0, showing mild to moderate PSMA uptake. Higher SUV_max was observed in lung and bone metastases. The longest tumor diameter (<i>R</i> = 0.190, <i>P</i> = 0.009) and tumor % growth rate (<i>R</i> = 0.220, <i>P</i> = 0.006) were significantly correlated with SUV_max. A longer duration from diagnosis was a relevant factor for high [⁶⁸Ga]Ga-PSMA-11 uptake. Seven patients received ¹⁷⁷Lu-PSMA therapy, but therapeutic outcomes were limited.</p><p><strong>Conclusion: </strong>High [⁶⁸Ga]Ga-PSMA-11 uptake in recurred or metastatic ACC was associated with location of metastases, longer tumor diameter, high tumor % growth rate, and a longer duration from diagnosis. While ¹⁷⁷Lu-PSMA therapy was performed in a limited cohort and outcomes were preliminary, these findings provide exploratory insights into potential factors relevant for patient selection and warrant further investigation in larger studies.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13139-025-00955-9.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"21-28"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Stress Myocardial Blood Flow in Patients Receiving Enhanced External Counter Pulsation (EECP) Therapy Measured by [¹⁵O]H₂O PET/CT: Pilot Study.","authors":"Anchisa Kunawudhi, Attapon Jantarato, Peerapon Kiatkittikul, Dheeratama Siripongsatian, Natphimol Boonkawin, Phornpa Lertutsahakul, Sunida Khamjit, Chanisa Chotipanich, Chetsadaporn Promteangtrong","doi":"10.1007/s13139-025-00970-w","DOIUrl":"https://doi.org/10.1007/s13139-025-00970-w","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the impact of Enhanced External Counterpulsation (EECP) therapy on myocardial blood flow (MBF) during stress and rest conditions, as well as coronary flow reserve (CFR). These parameters were assessed using non-invasive oxygen-15-labeled water ([¹⁵O]H₂O) positron emission tomography/computed tomography (PET/CT) myocardial perfusion imaging (MPI).</p><p><strong>Methods: </strong>Seven patients (six male, mean age 61.67 ± 9.33 years) with coronary artery disease completed 35 sessions of EECP therapy. All patients underwent [¹⁵O]H₂O PET/CT MPI during rest and adenosine-induced stress conditions before and after EECP treatment, within a one-month period. MBF and CFR were measured, and a paired t-test was used to evaluate the significance of EECP's effects (<i>p</i> < 0.05).</p><p><strong>Results: </strong>In a per-patient analysis, one patient had a normal [¹⁵O] H₂O PET/CT MPI study, while six had abnormal scans at pre-EECP, with no changes post-EECP. However, significant increases in stress MBF were observed per vascular territories (<i>p</i> = 0.023) and within the 17-segment model (<i>p</i> = 0.002) following EECP. Subgroup analysis showed a significant rise in stress MBF in segments with initially low stress MBF (<i>p</i> = 0.002) and in rest MBF in segments with normal pre-EECP stress MBF (<i>p</i> = 0.001). CFR increased significantly in segments with initially abnormal CFR (<i>p</i> = 0.0003) and decreased in segments with normal CFR (<i>p</i> = 0.007).</p><p><strong>Conclusion: </strong>In our small study group, EECP significantly improved MBF and CFR, particularly in stress-induced regions with significant CAD, as confirmed by [¹⁵O]H₂O PET/CT MPI.</p>","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"29-37"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioligand Therapy with Radiolabeled Somatostatin Analogues in Metastatic Bronchial Carcinoid: an Impressive Response.","authors":"Alberto Nieri, Luca Urso, Ilham Badrane, Sara Adamantiadis, Francesca Borgia, Corrado Cittanti, Mirco Bartolomei","doi":"10.1007/s13139-025-00941-1","DOIUrl":"https://doi.org/10.1007/s13139-025-00941-1","url":null,"abstract":"","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"60 1","pages":"51-53"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}